NKTR vs. OMER, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTS
Should you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.
Nektar Therapeutics vs. Its Competitors
Nektar Therapeutics (NASDAQ:NKTR) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, community ranking, analyst recommendations, valuation and media sentiment.
75.9% of Nektar Therapeutics shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 5.3% of Nektar Therapeutics shares are owned by insiders. Comparatively, 12.3% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Nektar Therapeutics presently has a consensus price target of $67.50, suggesting a potential upside of 589.48%. Omeros has a consensus price target of $18.00, suggesting a potential upside of 370.59%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Nektar Therapeutics is more favorable than Omeros.
In the previous week, Omeros had 1 more articles in the media than Nektar Therapeutics. MarketBeat recorded 11 mentions for Omeros and 10 mentions for Nektar Therapeutics. Nektar Therapeutics' average media sentiment score of 0.90 beat Omeros' score of 0.77 indicating that Nektar Therapeutics is being referred to more favorably in the media.
Omeros received 114 more outperform votes than Nektar Therapeutics when rated by MarketBeat users. Likewise, 70.61% of users gave Omeros an outperform vote while only 70.58% of users gave Nektar Therapeutics an outperform vote.
Nektar Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Omeros has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500.
Omeros has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -180.70%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.
Summary
Omeros beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Nektar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nektar Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NKTR) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy NKTR Stock Free NKTR Stock Alerts